Group 1 - Jiangsu Tianlong Medical Technology Co., Ltd. has been established with a registered capital of 10 million yuan [1] - The legal representative of the company is Liang Jiaming [1] - The business scope includes the operation of Class III medical devices, sales of Class II and III radiation devices, software outsourcing services, development of basic artificial intelligence software, and sales of biological materials [1] Group 2 - The company is jointly held by Xian Tianlong Technology Co., Ltd., a subsidiary of Kehua Bio-engineering Co., Ltd. (stock code: 002022), and Hainan Yikang Medical Technology Co., Ltd. [1]

（文章来源：证券日报） 证券日报网讯科华生物9月3日在互动平台回答投资者提问时表示，公司控股股东西安致同持有公司5% 股份，并通过表决权委托方式控制公司10.64%表决权，合计控制公司15.64%表决权，为公司控制表决 权数量最多的股东；珠海保联持有公司13.64%股份，拥有公司3%表决权。在表决权委托期间，西安致 同与珠海保联构成一致行动人。西安致同与珠海保联合计控制公司18.64%表决权。若公司存在股份变 动涉及的披露事项，公司将严格按照法律法规的规定及时履行信息披露义务，请以公司披露的公告为 准。 ...

Core Viewpoint - The company has released its 2025 semi-annual report, confirming that the report accurately reflects its operational results and financial status without any misleading statements or omissions [6][14]. Group 1: Company Overview - The company did not distribute cash dividends or issue new shares during the reporting period [3]. - The number of shareholders and their holdings were disclosed, with a total of 13,696,600 shares held in the company's repurchase account, accounting for 2.66% of the total share capital [4]. Group 2: Board and Supervisory Committee Meetings - The 10th Supervisory Committee meeting was held on August 25, 2025, with all three supervisors present, and the meeting complied with relevant laws and regulations [6][12]. - The 10th Board of Directors meeting also took place on August 25, 2025, with all nine directors present, including three independent directors, and the meeting adhered to legal requirements [12][14]. Group 3: Fundraising and Usage - The company raised a total of RMB 738 million through the issuance of convertible bonds, with a net amount of RMB 718.53 million after deducting issuance costs [22]. - The company has established special accounts for managing the raised funds, ensuring compliance with regulatory requirements [25]. - As of June 30, 2025, the company reported no changes in the use of raised funds, and all funds remain in designated bank accounts for future investment projects [30][34].

Group 1 - The core point of the article is that Kehua Bio reported a decline in revenue and a net loss for the first half of 2025, indicating financial challenges for the company [1] Group 2 - For the first half of 2025, the company achieved operating revenue of 793,574,870.31 yuan, which represents a year-on-year decrease of 12.65% [1] - The net profit attributable to shareholders of the listed company was -133,452,683.41 yuan, indicating a significant loss [1]

Group 1 - The core point of the article is that Kehua Bio (SZ 002022) announced the receipt of a medical device registration certificate for its "Human Papillomavirus Nucleic Acid Typing Detection Kit" from the National Medical Products Administration [1] - As of January to June 2025, the revenue composition of Kehua Bio is 100% from the biopharmaceutical sector [1] - Kehua Bio's market capitalization is currently 3.8 billion yuan [1] Group 2 - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related companies [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海科华生物工程股份有限公司 证券代码：002022 证券简称：科华生物 公告编号：2025-047 债券代码：128124 债券简称：科华转债 关于产品获得医疗器械注册证的公告 特此公告。 上海科华生物工程股份有限公司董事会 2025年8月27日 近日，上海科华生物工程股份有限公司（以下简称"公司"）控股子公司苏 州天隆生物科技有限公司收到国家药品监督管理局颁发的医疗器械注册证（体外 诊断试剂）。具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期 | 适用范围/预期用途 | | --- | --- | --- | --- | --- | | | 人乳头瘤 病毒核酸 分型检测 | 国械注准 | 2025年08月25日 至 | 本试剂盒适用于体外定性 检测女性宫颈脱落细胞样 本中21种人乳头瘤病毒 DNA核酸（具体包括HPV 16，18，26，31，33，35， | | 1 | | | | | | | 试剂盒（荧光 | 20253401705 | 2030年08月24日 | 39，45，51， ...

Core Viewpoint - Kehua Bio's 2025 semi-annual report indicates a significant decline in revenue and a net loss for the company [1] Financial Performance - The company achieved an operating revenue of 794 million yuan, representing a year-on-year decrease of 12.65% [1] - The net loss attributable to shareholders of the listed company was 133 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 140 million yuan [1] - The basic loss per share was 0.2595 yuan [1]

| 非经营性资金占用 | 资金占用方名称 | 占用方与上市 公司的关联关 | 上市公司核算的 | 2025 年期初占 | 2025 年半年度 占用累计发生 | 2025 年半年度占 用资金的利息(如 | 2025 年半年度偿 | 2025年6月末占 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 系 | 会计科目 | 用资金余额 | 金额 （不含利息） | 有) | 还累计发生金额 | 用资金余额 | 原因 | | | 控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | - | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际控 制人及其附属企业 | | | | | | | | | | - | | 小计 | - | - | - | | | | | | - | - | | 其他关联方及其附属 企业 | | | | | | | | | | - | | 小计 | | | ...

上海科华生物工程股份有限公司 2025 年半年度财务报告 上海科华生物工程股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 上海科华生物工程股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：上海科华生物工程股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 817,502,589.16 | 864,626,234.89 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 274,487.85 | 293,591.40 | | 衍生金融资产 | | | | 应收票据 | 11,236,897.68 | 6,319,069.02 | | 应收账款 | 821,405,335.39 | 871,302,109.00 | | 应收款项融资 | 12,837,294.94 | 6,595,820.95 ...

（一） 实际募集资金金额及资金到账时间 经中国证券监督管理委员会《关于核准上海科华生物工程股份有限公司公开 发行可转换公司债券的批复》（证监许可［2020］970 号）核准，公司向社会公 开发行面值总额人民币 73,800 万元可转换公司债券（以下简称"可转债"）， 期限 6 年。截至 2020 年 8 月 4 日止，公司实际公开发行可转债 738 万张，每张 面值为人民币 100 元，按面值平价发行，认购资金总额为人民币 738,000,000.00 元，募集资金总额扣减本次可转债发行的承销保荐费用人民币 15,645,600.00 元（含增值税），实际收到可转债认购资金为人民币 722,354,400.00 元。本次 发行费用（除承销保荐费用）包括律师费人民币 1,743,591.44 元（含增值税）、 审计及验资费用人民币 1,161,250.00 元（含增值税）、资信评级费人民币 550,000.00 元（含增值税）、用于本次发行的信息披露费用人民币 600,000.00 元（含增值税）、发行手续费及其他费用人民币 263,800.00 元（含增值税）， 共计人民币 4,318,641.44 元（含增 ...